Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Aug;103(1-3):104-9.
doi: 10.1016/j.schres.2008.04.023. Epub 2008 Jun 4.

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

Jonathan M Meyer  1 , Vicki G Davis, Joseph P McEvoy, Donald C Goff, Henry A Nasrallah, Sonia M Davis, Gail L Daumit, John Hsiao, Marvin S Swartz, T Scott Stroup, Jeffrey A Lieberman
Affiliations
Clinical Trial

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1

Jonathan M Meyer et al. Schizophr Res. 2008 Aug.

Abstract

Background: Recent literature documents a stronger association between nonfasting triglycerides (TG) and cardiovascular risk compared to fasting TG. Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial.

Methods: Change in nonfasting TG, adjusted for baseline value, was compared between antipsychotic treatment groups using subjects with nonfasting laboratory assessments at baseline and 3 months.

Results: Among the 246 subjects there were significant treatment differences in 3-month change from baseline (p=0.009). The greatest increases in median and adjusted mean nonfasting TG levels were seen among those randomized to quetiapine (mean+54.7 mg/dl, median+26 mg/dl) and olanzapine (mean+23.4 mg/dl, median+26.5 mg/dl), while ziprasidone was neutral (mean+0.0 mg/dl, median+8 mg/dl), and decreases were seen with risperidone (mean -18.4 mg/dl, median -6.5 mg/dl) and perphenazine (mean -1.3 mg/dl, median -22 mg/dl). Pairwise comparisons indicated a significant between-group difference for perphenazine vs. olanzapine (p=0.002) and a trend for perphenazine vs. quetiapine (p=0.006).

Conclusions: This analysis provides further evidence for differential antipsychotic metabolic liabilities, and confirms signals for the effects of olanzapine and quetiapine on serum TG seen in earlier CATIE analyses. Future consensus recommendations will clarify the role of nonfasting TG monitoring in routine clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median Baseline Nonfasting Triglyceride (TG) Values By Time Since Last Meal * IQ = Interquartile Range 25th – 75th Percentile
See this image and copyright information in PMC

References

    1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Journal of Clinical Psychiatry. 2004;65:267–272. - PubMed
    1. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–316. - PubMed
    1. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectrums. 2007;12:12–20. - PubMed
    1. Multiple Risk Factor Intervention Trial Research, G. Eberly LE, Stamler J, Neaton JD. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine. 2003;163:1077–1083. - PubMed
    1. Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nasrallah HA, Daumit G, Lamberti S, D’Agnostino RB, Stroup TS, Lieberman JA. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophrenia Research. 2005;80:45–53. - PubMed

Publication types

MeSH terms